8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 26, 2016)

Filed April 26, 2016For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on April 26, 2016, to report its financial results for the first quarter of 2016. The primary focus of this filing is the dissemination of the company's Q1 2016 earnings press release, which is attached as Exhibit 99.1 and incorporated by reference. Investors should note that this information is furnished and not deemed "filed" under the Securities Exchange Act of 1934. While the 8-K itself is procedural, the attached press release contains the critical financial and operational details investors need to assess the company's performance. Key information typically found in such releases includes revenue figures, earnings per share (EPS), segment performance (e.g., transcatheter heart valves, critical care), and forward-looking guidance. Investors should review Exhibit 99.1 for specific figures and management commentary on trends and outlook.

Key Highlights

  • 1Edwards Lifesciences (EW) announced its first quarter 2016 financial results on April 26, 2016.
  • 2The 8-K filing primarily serves to furnish the company's Q1 2016 earnings press release as Exhibit 99.1.
  • 3The furnished press release is incorporated by reference into the 8-K.
  • 4Information provided under Item 2.02 is furnished, not deemed 'filed' for regulatory purposes.
  • 5Investors should refer to the press release (Exhibit 99.1) for detailed financial performance and operational highlights for Q1 2016.
  • 6The filing indicates a focus on the company's results and financial condition for the specified quarter.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report and provide access to Edwards Lifesciences' financial results for the first quarter of 2016, as detailed in their accompanying press release.

The detailed financial results for Q1 2016 are contained within the press release furnished as Exhibit 99.1 to this 8-K filing. You should refer to that document for specific revenue, EPS, and other financial metrics.

No, the information furnished under Item 2.02 of this 8-K, including the press release, is not deemed 'filed' for the purposes of the Securities Exchange Act of 1934. This means it does not carry the same liability as formally filed information.

Investors should look for key metrics such as total revenue, revenue breakdown by product segment (e.g., Transcatheter Heart Valves, Surgical Heart Valves, Critical Care, Advanced Monitoring), earnings per share (EPS), and any forward-looking guidance or outlook provided by management for the remainder of 2016.